Biocept Revenue vs. Net Income

BIOCQ Stock   0.0001  0.0001  50.00%   
Based on Biocept's profitability indicators, Biocept may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in January. Profitability indicators assess Biocept's ability to earn profits and add value for shareholders.
 
Total Revenue  
First Reported
2010-12-31
Previous Quarter
29.7 M
Current Value
33 M
Quarterly Volatility
16.2 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
At this time, Biocept's Price To Sales Ratio is relatively stable compared to the past year. As of 12/28/2025, Price Sales Ratio is likely to grow to 0.13, while Days Sales Outstanding is likely to drop 33.17. As of 12/28/2025, Income Quality is likely to grow to 0.72, while Net Interest Income is likely to drop (298.6 K).
For Biocept profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Biocept to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Biocept utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Biocept's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Biocept over time as well as its relative position and ranking within its peers.
Check out Trending Equities.
To learn how to invest in Biocept Stock, please use our How to Invest in Biocept guide.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biocept. If investors know Biocept will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biocept listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(48.17)
Revenue Per Share
1.965
Quarterly Revenue Growth
(0.90)
Return On Assets
(0.52)
Return On Equity
(1.87)
The market value of Biocept is measured differently than its book value, which is the value of Biocept that is recorded on the company's balance sheet. Investors also form their own opinion of Biocept's value that differs from its market value or its book value, called intrinsic value, which is Biocept's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biocept's market value can be influenced by many factors that don't directly affect Biocept's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Biocept's value and its price as these two are different measures arrived at by different means. Investors typically determine if Biocept is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biocept's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Biocept Net Income vs. Revenue Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Biocept's current stock value. Our valuation model uses many indicators to compare Biocept value to that of its competitors to determine the firm's financial worth.
Biocept is the top company in revenue category among its peers. It is rated second in net income category among its peers . At this time, Biocept's Total Revenue is relatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Biocept by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.

Biocept Revenue vs. Competition

Biocept is the top company in revenue category among its peers. Market size based on revenue of Health Care industry is currently estimated at about 73.43 Million. Biocept totals roughly 25.86 Million in revenue claiming about 35% of equities under Health Care industry.

Biocept Net Income vs. Revenue

Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.

Biocept

Revenue

 = 

Money Received

-

Discounts and Returns

 = 
25.86 M
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.

Biocept

Net Income

 = 

(Rev + Gain)

-

(Exp + Loss)

 = 
(32.09 M)
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.

Biocept Net Income Comparison

Biocept is currently under evaluation in net income category among its peers.

Biocept Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Biocept, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Biocept will eventually generate negative long term returns. The profitability progress is the general direction of Biocept's change in net profit over the period of time. It can combine multiple indicators of Biocept, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for Next Year
Net Interest Income-284.4 K-298.6 K
Operating Income-28.8 M-30.2 M
Net Loss-28.9 M-30.3 M
Income Before Tax-29 M-30.4 M
Total Other Income Expense Net-263.4 K-276.5 K
Net Loss-28.9 M-30.3 M
Income Tax Expense-112.5 K-106.9 K
Net Loss(51.10)(53.66)
Income Quality 0.48  0.72 
Net Income Per E B T 1.15  1.10 

Biocept Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Biocept. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Biocept position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Biocept's important profitability drivers and their relationship over time.

Use Biocept in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Biocept position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Biocept will appreciate offsetting losses from the drop in the long position's value.

Biocept Pair Trading

Biocept Pair Trading Analysis

The ability to find closely correlated positions to Biocept could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Biocept when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Biocept - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Biocept to buy it.
The correlation of Biocept is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Biocept moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Biocept moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Biocept can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Biocept position

In addition to having Biocept in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Biotech Thematic Idea Now

Biotech
Biotech Theme
Companies specialized in biotechnology production and delivery of pharmaceuticals services. The Biotech theme has 17 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Biotech Theme or any other thematic opportunities.
View All  Next Launch

Additional Tools for Biocept Stock Analysis

When running Biocept's price analysis, check to measure Biocept's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biocept is operating at the current time. Most of Biocept's value examination focuses on studying past and present price action to predict the probability of Biocept's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biocept's price. Additionally, you may evaluate how the addition of Biocept to your portfolios can decrease your overall portfolio volatility.